167 related articles for article (PubMed ID: 35008547)
1. Bioprinted Cancer Model of Neuroblastoma in a Renal Microenvironment as an Efficiently Applicable Drug Testing Platform.
Wu D; Berg J; Arlt B; Röhrs V; Al-Zeer MA; Deubzer HE; Kurreck J
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008547
[TBL] [Abstract][Full Text] [Related]
2. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
3. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
[TBL] [Abstract][Full Text] [Related]
4. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells.
Wang G; Edwards H; Caldwell JT; Buck SA; Qing WY; Taub JW; Ge Y; Wang Z
PLoS One; 2013; 8(9):e76662. PubMed ID: 24098799
[TBL] [Abstract][Full Text] [Related]
5. Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model.
Waldeck K; Cullinane C; Ardley K; Shortt J; Martin B; Tothill RW; Li J; Johnstone RW; McArthur GA; Hicks RJ; Wood PJ
Int J Cancer; 2016 Jul; 139(1):194-204. PubMed ID: 26914605
[TBL] [Abstract][Full Text] [Related]
6. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.
Faisal A; Vaughan L; Bavetsias V; Sun C; Atrash B; Avery S; Jamin Y; Robinson SP; Workman P; Blagg J; Raynaud FI; Eccles SA; Chesler L; Linardopoulos S
Mol Cancer Ther; 2011 Nov; 10(11):2115-23. PubMed ID: 21885865
[TBL] [Abstract][Full Text] [Related]
7. Combined Inhibition of ALK and HDAC Induces Synergistic Cytotoxicity in Neuroblastoma Cell Lines.
Hagiwara K; Tokunaga T; Iida H; Nagai H
Anticancer Res; 2019 Jul; 39(7):3579-3584. PubMed ID: 31262882
[TBL] [Abstract][Full Text] [Related]
8. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
Shen J; Najafi S; Stäble S; Fabian J; Koeneke E; Kolbinger FR; Wrobel JK; Meder B; Distel M; Heimburg T; Sippl W; Jung M; Peterziel H; Kranz D; Boutros M; Westermann F; Witt O; Oehme I
Cell Death Differ; 2018 Dec; 25(12):2053-2070. PubMed ID: 29515255
[TBL] [Abstract][Full Text] [Related]
9. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
[TBL] [Abstract][Full Text] [Related]
10. Anticancer efficacy of p-dodecylaminophenol against high-risk and refractory neuroblastoma cells in vitro and in vivo.
Takahashi N; Koyama S; Hasegawa S; Yamasaki M; Imai M
Bioorg Med Chem Lett; 2017 Oct; 27(20):4664-4672. PubMed ID: 28927789
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway.
Chen Y; Tsai YH; Tseng SH
Surgery; 2013 Jan; 153(1):4-16. PubMed ID: 22703967
[TBL] [Abstract][Full Text] [Related]
12. ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation.
Borenäs M; Umapathy G; Lai WY; Lind DE; Witek B; Guan J; Mendoza-Garcia P; Masudi T; Claeys A; Chuang TP; El Wakil A; Arefin B; Fransson S; Koster J; Johansson M; Gaarder J; Van den Eynden J; Hallberg B; Palmer RH
EMBO J; 2021 Feb; 40(3):e105784. PubMed ID: 33411331
[TBL] [Abstract][Full Text] [Related]
13. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
14. Targeting anaplastic lymphoma kinase (ALK) gene alterations in neuroblastoma by using alkylating pyrrole-imidazole polyamides.
Ota Y; Yoda H; Inoue T; Watanabe T; Shinozaki Y; Takatori A; Nagase H
PLoS One; 2021; 16(9):e0257718. PubMed ID: 34591871
[TBL] [Abstract][Full Text] [Related]
15. The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line.
Yi B; Yang J; Wang L
Tumour Biol; 2014 Apr; 35(4):3229-35. PubMed ID: 24293393
[TBL] [Abstract][Full Text] [Related]
16. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
[TBL] [Abstract][Full Text] [Related]
17. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
18. Burkholderia Lethal Factor 1, a Novel Anti-Cancer Toxin, Demonstrates Selective Cytotoxicity in MYCN-Amplified Neuroblastoma Cells.
Rust A; Shah S; Hautbergue GM; Davletov B
Toxins (Basel); 2018 Jun; 10(7):. PubMed ID: 29954071
[TBL] [Abstract][Full Text] [Related]
19. Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma.
Xiao L; Somers K; Murray J; Pandher R; Karsa M; Ronca E; Bongers A; Terry R; Ehteda A; Gamble LD; Issaeva N; Leonova KI; O'Connor A; Mayoh C; Venkat P; Quek H; Brand J; Kusuma FK; Pettitt JA; Mosmann E; Kearns A; Eden G; Alfred S; Allan S; Zhai L; Kamili A; Gifford AJ; Carter DR; Henderson MJ; Fletcher JI; Marshall G; Johnstone RW; Cesare AJ; Ziegler DS; Gudkov AV; Gurova KV; Norris MD; Haber M
Clin Cancer Res; 2021 Aug; 27(15):4338-4352. PubMed ID: 33994371
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.
Chesler L; Goldenberg DD; Collins R; Grimmer M; Kim GE; Tihan T; Nguyen K; Yakovenko S; Matthay KK; Weiss WA
Neoplasia; 2008 Nov; 10(11):1268-74. PubMed ID: 18953436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]